Acasă › Limfom non-Hodgkin › Massachusetts › Boston
Studii clinice pentru Limfom non-Hodgkin în Boston, MA
26 studii pentru Limfom non-Hodgkin caută participanți în și în jurul orașului Boston (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
În curs de recrutareFaza 1/2
- Dana Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
În curs de recrutareFaza 2
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
În curs de recrutareFaza 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
În curs de recrutareFaza 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
În curs de recrutareFaza 1/2
- Research Site, Boston
- Research Site, Boston
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
În curs de recrutareFaza 1/2
- Dana-Farber Cancer Institute, Boston
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
În curs de recrutareFaza 2
- Boston Medical Center, Boston
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
În curs de recrutareFaza 2
- Dana-Farber Cancer Institute, Boston
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
În curs de recrutareFaza 1
- Tufts Medical Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
În curs de recrutareFaza 1/2
- Dana-Farber Cancer Institute, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
În curs de recrutareFaza 1/2
- Massachusetts General Hospital, Boston
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
În curs de recrutareStudiu observațional
- Dana Farber Cancer Institute, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
În curs de recrutareFaza 1Voluntari sănătoși bineveniți
- Brigham and Women's Hospital, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
În curs de recrutareFaza 2
- Dana Farber Cancer Institute, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
În curs de recrutareStudiu observațional
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
În curs de recrutareFaza 1
- Dana Farber Cancer Institute, Boston
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
În curs de recrutareStudiu observațional
- Dana-Farber Cancer Institute, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
În curs de recrutareFaza 1/2
- Dana Farber Cancer Institute, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
În curs de recrutare
- Dana Farber Cancer Institute, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
În curs de recrutareFaza 1
- Massachusetts General Hospital, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
În curs de recrutareFaza 2
- Beth Israel Deaconess Medical Center, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
În curs de recrutareFaza 2Voluntari sănătoși bineveniți
- DFCI/BWH Brigham and Women's Hospital, Boston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
În curs de recrutareFaza 4
- Dana-Farber Cancer Institute, Boston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
În curs de recrutareFaza 4
- Dana-Farber Cancer Institute, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
În curs de recrutareFaza 1
- Beth Israel Deaconess Medical Center, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
În curs de recrutareFaza 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Studii pentru Limfom non-Hodgkin în alte orașe
- New York City, NY31 studii
- Houston, TX31 studii
- Nashville, TN21 studii
- Philadelphia, PA20 studii
- Baldwin Park, CA19 studii
- Washington, DC18 studii
- Chicago, IL18 studii
- Atlanta, GA18 studii
- Milwaukee, WI18 studii
- Columbus, OH18 studii
- Dallas, TX17 studii
- Seattle, WA16 studii
Alte studii în Boston
- Cancer de sân112 studii
- Cancer pulmonar cu celule non-pătrate90 studii
- Cancer (toate tipurile)85 studii
- Cancer metastatic63 studii
- Cancer colorectal63 studii
- Cancer pulmonar62 studii
- Cancer ovarian61 studii
- Cancer de prostată59 studii
- Depresie52 studii
- Cancer endometrial50 studii
- Insuficiență cardiacă44 studii
- Leucemie mieloasă acută44 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.